Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:BTO News 29 December 2025 - 12 January 2026

BillionToOne stock in focus before Monday open after Friday jump, JPMorgan conference next

BillionToOne stock in focus before Monday open after Friday jump, JPMorgan conference next

NEW YORK, December 29, 2025, 05:02 ET — Premarket BillionToOne, Inc shares rose 3.4% to $89.30 at Friday’s close. The stock last traded at $89.40 in after-hours activity, trading that takes place after the regular session ends, according to Investing.com. Investing.com The newly public molecular diagnostics company heads into the final trading week of the year with few near-term catalysts before a big healthcare investor conference in January. Nasdaq BillionToOne’s most recent quarterly report set a high bar: the company posted sharp revenue growth and swung to operating profit, while issuing full-year revenue guidance, it said in a results release
29 December 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
New York, Feb 7, 2026, 09:33 (ET) — Market closed. MARA Holdings, Inc. shares ended Friday up 22.3% at $8.24, with about 82.4 million shares traded. Bitcoin was last around $68,928 on Saturday. The weekend pause matters because miners like MARA have become a fast, sometimes messy read-through on risk appetite. “The market looks like it was getting a bit overdone to the downside,” said Robert Pavlik, a senior portfolio manager at Dakota Wealth, pointing to technical buying after a rough stretch for tech and other risk assets. (Reuters) That sensitivity cuts both ways. A Reuters report this week said
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop